Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its stake in shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 75.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,845 shares of the specialty pharmaceutical company’s stock after acquiring an additional 17,190 shares during the period. Russell Investments Group Ltd.’s holdings in Eagle Pharmaceuticals were worth $2,218,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. New York State Teachers Retirement System increased its position in Eagle Pharmaceuticals by 2.2% during the first quarter. New York State Teachers Retirement System now owns 9,677 shares of the specialty pharmaceutical company’s stock worth $489,000 after purchasing an additional 208 shares during the last quarter. Strs Ohio raised its stake in Eagle Pharmaceuticals by 4.2% during the second quarter. Strs Ohio now owns 12,400 shares of the specialty pharmaceutical company’s stock worth $690,000 after purchasing an additional 500 shares during the period. US Bancorp DE raised its stake in Eagle Pharmaceuticals by 7.4% during the first quarter. US Bancorp DE now owns 7,842 shares of the specialty pharmaceutical company’s stock worth $396,000 after purchasing an additional 543 shares during the period. Financial Gravity Wealth Inc. acquired a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at $33,000. Finally, First Quadrant L P CA acquired a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at $34,000. 97.51% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Hudson Executive Capital Lp sold 1,112 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $60.06, for a total value of $66,786.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.70% of the stock is owned by corporate insiders.



A number of research firms have recently commented on EGRX. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 price objective for the company in a report on Wednesday, August 14th. ValuEngine cut Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 28th. Royal Bank of Canada reissued a “buy” rating and set a $66.00 price target on shares of Eagle Pharmaceuticals in a research report on Sunday, August 11th. Finally, BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $58.80.

NASDAQ EGRX traded up $1.30 during mid-day trading on Thursday, hitting $59.34. The company’s stock had a trading volume of 1,726 shares, compared to its average volume of 144,366. Eagle Pharmaceuticals Inc has a 52-week low of $36.03 and a 52-week high of $70.13. The stock’s fifty day simple moving average is $56.49 and its two-hundred day simple moving average is $53.18. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.59 and a quick ratio of 3.36. The firm has a market capitalization of $803.07 million, a P/E ratio of 28.20 and a beta of 1.42.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.17. Eagle Pharmaceuticals had a net margin of 19.79% and a return on equity of 24.10%. The firm had revenue of $56.70 million for the quarter, compared to analysts’ expectations of $53.61 million. During the same period in the previous year, the company posted $0.99 earnings per share. Eagle Pharmaceuticals’s revenue was down 4.4% compared to the same quarter last year. On average, equities analysts forecast that Eagle Pharmaceuticals Inc will post 2.48 earnings per share for the current fiscal year.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Further Reading: What causes a yield curve to invert?

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.